Empowering Discoveries in Oncology

At Sysmex Inostics, we are pioneers in liquid biopsy who are on a mission to defeat cancer. As innovators in cancer detection, we have a deep knowledge of circulating tumor DNA (ctDNA) dynamics. Sysmex Inostics' ultra-sensitive liquid biopsy solutions were designed to deliver exquisite ctDNA detection to answer the most important clinical questions, both in the patient care setting as well as in BioPharma clinical development.

Latest news and press releases

Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Sysmex Inostics’ OncoBEAM™ RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Sysmex Corporation received Insurance Coverage in Japan for Liquid Biopsy RAS Gene Mutation Testing  for CRC Using High-Sensitivity Digital PCR
Sysmex Inostics’ Colorectal Cancer Blood-Based OncoBEAM™ RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing demonstrate clearance of ctDNA correlates w/ pathologic complete response in breast cancer patients during neoadjuvant treatment